argenx SE (ARGX) PT Raised to $283 at Wedbush, Following Pharma Study Data Release
- Wall Street falls with Amazon; S&P 500 posts sixth straight month of gains
- Amazon (AMZN) Plunges After Missing Sales and Guidance Expectations, Analysts Slash PTs to Reflect Weaker Guidance
- Pinterest (PINS) Tops Profit and Sales Views, But Shares Plunges Over 20% on a Big Monthly User Miss to Prompt Two Downgrades
- 'I'm CEO.' New Book Outlines Merger Conversations Between Elon Musk and Tim Cook
- Bullard: Fed should taper this fall, go "fairly rapidly" to end early 2022
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Wedbush analyst David Nierengarten raised the price target on argenx SE (NASDAQ: ARGX) to $283.00 (from $253.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update
- Denso Corp. (6902:JP) (DNZOY) PT Raised to JPY9,000 at Macquarie
- Mandom Corp. (4917:JP) (MDOMF) PT Lowered to KRW1,200 at CLSA
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!